Globus Medical, Inc. $GMED Shares Bought by Park Avenue Securities LLC

Park Avenue Securities LLC grew its position in Globus Medical, Inc. (NYSE:GMED) by 45.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 25,034 shares of the medical device company’s stock after buying an additional 7,789 shares during the period. Park Avenue Securities LLC’s holdings in Globus Medical were worth $1,875,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Janus Henderson Group PLC grew its stake in shares of Globus Medical by 4.5% during the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after purchasing an additional 328,217 shares during the period. Sculptor Capital LP lifted its holdings in Globus Medical by 1.9% during the first quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock valued at $263,477,000 after purchasing an additional 58,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Globus Medical by 2.0% during the first quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock valued at $152,474,000 after purchasing an additional 33,976 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Globus Medical by 2.8% in the first quarter. The Manufacturers Life Insurance Company now owns 1,132,278 shares of the medical device company’s stock worth $97,557,000 after purchasing an additional 30,412 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Globus Medical by 107.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 912,905 shares of the medical device company’s stock worth $78,656,000 after purchasing an additional 471,875 shares during the period. 95.16% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on GMED. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a report on Friday, September 18th. Royal Bank Of Canada cut their price objective on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research report on Thursday, October 1st. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a report on Friday, October 9th. UBS Group began coverage on shares of Globus Medical in a research note on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price objective for the company. Finally, BMO Capital Markets started coverage on Globus Medical in a research note on Wednesday, July 8th. They set an “outperform” rating and a $94.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Globus Medical presently has a consensus rating of “Moderate Buy” and an average price target of $99.46.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research raised EPS estimates across multiple periods, including Q3 2026 to $1.19, FY2026 to $4.98, FY2027 to $5.07, and FY2028 to $5.89. The firm also lifted estimates for Q1 2027, Q2 2027 and Q2 2028 by $0.01 each and maintained a “Strong-Buy” rating. The revisions suggest modestly improving expectations for Globus Medical’s earnings outlook. MarketBeat Globus Medical analyst estimates
• Positive Sentiment: Globus Medical was highlighted as a healthcare technology stock positioned for digital-health growth. Zacks cited projected 2026 earnings growth, an attractive valuation and innovation in essential medical services as reasons the company could benefit from broader healthcare technology adoption. Zacks healthcare technology stocks article
• Positive Sentiment: Another analysis called GMED undervalued even after a 77% run. This supports the view that analysts see additional upside based on Globus Medical’s earnings prospects and valuation, although the large prior gain may also encourage profit-taking. Globus Medical stock looks undervalued article
• Neutral Sentiment: The estimate increases were small—generally just $0.01 per share—and Zacks’ FY2026 estimate of $4.98 remains slightly below the broader consensus of $4.99. As a result, the revisions provide incremental support but may not be strong enough to overcome near-term selling pressure.
• Negative Sentiment: With GMED having already advanced substantially, investors may be locking in gains while waiting for a larger earnings or guidance catalyst. This profit-taking dynamic appears to be outweighing the otherwise favorable analyst commentary today.

Insider Activity

In other Globus Medical news, Director Stephen Zarrilli sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director James R. Tobin sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the transaction, the director directly owned 15,000 shares of the company’s stock, valued at $1,118,700. This trade represents a 66.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 18.38% of the stock is owned by corporate insiders.

Globus Medical Stock Down 5.9%

Shares of NYSE GMED opened at $77.98 on Friday. Globus Medical, Inc. has a twelve month low of $59.51 and a twelve month high of $101.40. The firm has a market cap of $10.47 billion, a PE ratio of 19.94, a price-to-earnings-growth ratio of 1.26 and a beta of 0.96. The business has a fifty day simple moving average of $77.64 and a two-hundred day simple moving average of $83.51.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.24. The business had revenue of $789.61 million for the quarter, compared to the consensus estimate of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The business’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, research analysts expect that Globus Medical, Inc. will post 4.99 earnings per share for the current year.

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.